research The Evaluation of the Role of Androgens in Hirsutism and the Use of a New Anti-androgen “Cyproterone Acetate” for Therapy
Cyproterone acetate combined with ethinyl estradiol significantly reduced hirsutism in women.
Search
for
Sort by
Research
720-750 / 1000+ results
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research OA08 Ocrelizumab in pregnancy in a patient with juvenile onset systemic lupus erythematosus
Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.
research A case of refractory alopecia areata successfully treated by combining delgocitinib ointment with excimer laser
Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.
research Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study
Low-dose naltrexone may help reduce redness in certain scalp conditions.
research EPH39 Alopecia Areata: Targeted Review of Adverse Events Associated with Clinical Studies of Treatments
research Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist
The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
research Reduced serum vitamin B12 levels during oral cyproterone-acetate and ethinyl-oestradiol therapy in women with diffuse androgen-dependent alopecia
Taking cyproterone acetate and ethinyl oestradiol for hair loss can lower vitamin B12 levels in women.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Development, Optimization, and In Vitro/In Vivo Evaluation of Azelaic Acid Transethosomal Gel for Antidermatophyte Activity
Azelaic acid in a special gel is more effective against skin fungi than regular azelaic acid.
research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
research THU0239 Methotrexate Dose has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial
Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
research Alopecia areata – Current understanding and management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research COMPARISON OF EFFICACY OF VARIOUS TOPICAL TREATMENT MODALITIES IN ALOPECIA AREATA
0.05% Betamethasone Dipropionate is the most effective topical treatment for alopecia areata.
research Isotretinoin으로 치료한 농양성 천굴성 두부모낭주위염
Isotretinoin treatment improved scalp condition and stopped hair loss.
research New Treatment Options for Alopecia Areata
Baricitinib is a new, effective treatment for advanced alopecia areata but is costly and has risks.
research Peripheral neuropathy associated with tofacitinib use in alopecia universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Microneedling with Triamcinolone acetonide versus Intralesional Triamcinolone acetonide in treatment of Alopecia Areata
Microneedling with triamcinolone is a safe, effective, and less painful treatment for alopecia areata.
research Resolution of refractory systemic lupus erythematosus-associated alopecia with anifrolumab: a case report
research Characterization of an autoimmune condition associated with AEC syndrome
Controlling Tslp can improve health in AEC syndrome patients.
research Topical sodium valproate-loaded nanospanlastics versus conventional topical steroid therapy in alopecia areata: a randomized controlled study
Both treatments for alopecia areata showed similar modest effectiveness.
research Comparison of cyclosporine and betamethasone minipulse therapy in management of Alopecia Areata
Oral cyclosporine works better than betamethasone minipulse therapy for treating Alopecia Areata.
research Recovery of resistant alopecia areata treated with tofacitinib: An 8-year-old child's case report
Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis
Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
research [Long-term treatment of virilized women with cyproterone acetate (author's transl)].
Cyproterone acetate effectively treats virilized women, especially under 35, despite some side effects.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.